RPRX
Royalty Pharma
RPRX
Meridian score25
QualityQuality: 4th percentile
MomentumMomentum: 79th percentile
GrowthGrowth: 18th percentile
ValuationValuation: 55th percentile
ExpectationsExpectations: 40th percentile
ResearchNot researched
Evidence to review
- Financial comparability: Goodwill and intangible assets increased materially; review acquisition effects.
- Financial comparability: Large balance-sheet line-item shifts may reflect reclassification.
Stage and trend
Stage 2 · AdvancingAbove 21d: yesAbove 50d: yesAbove 200d: yes50d over 200d: yes
Weeks in stage94 · week open
30-week lineRising
From 30-week line+15.5%
Price · Oct 27$65.28
From 52w high-0.3%
Relative volume0.8x
1M+11.8%
3M+10.8%
6M+32.9%